Neutropenic Enterocolitis Associated with Docetaxel-based Chemotherapy in a Patient with Breast Carcinoma

Haldun Kar, Necat Cin, Özgün Akgül, Cengiz Tavusbay, Yasin Peker, Fatma Tatar
Department of General Surgery, Katip Çelebi University Atatürk Training and Research Hospital, İzmir, Turkey

ABSTRACT

Introduction: Neutropenic enterocolitis (NE) is a rare but often life-threatening complication associated with taxane-based chemotherapy in patients with cancer.

Case Report: A 39-year-old woman with a diagnosis of breast carcinoma underwent breast conserving surgery for the right breast. She was treated with docetaxel, cyclophosphamide, and epirubicin for the following months. Seven days after receiving the first dose of chemotherapy, she was presented to our emergency center with diarrhea, vomiting, fever, and diffuse abdominal pain. Abdominal examination revealed right lower quadrant tenderness with rebound. Blood work revealed severe neutropenia and leucopenia. Computed tomography demonstrated thickening of the walls of the ascending and transverse colon. Furthermore, emergency laparotomy revealed a necrotic hepatic flexura without perforation. Right hemicolectomy was performed; the biopsy revealed acute hemorrhagic infarction of the colon.

Conclusion: Patients with breast carcinoma presenting with acute abdominal pain, neutropenia, and radiologically demonstrable bowel wall thickening while receiving taxane-based chemotherapy should be suspected of having NE.

Keywords: Neutropenic enterocolitis, docetaxel, chemotherapy

Received: 05.10.2015   Accepted: 14.11.2015   Available Online Date: 04.02.2016

Introduction
Neutropenic enterocolitis (NE) is a clinical syndrome that can occur because of neutropenia induced by a disease or chemotherapy (1). It is mostly reported in adults with leukemia. Although the true incidence of the disease is unknown, it is estimated that 5% of adults undergoing chemotherapy for solid malignant tumors suffer from NE (1, 2). Docetaxel is a well-known taxane-based drug with high antitumor activity in different solid tumors. NE is reported as a life-threatening complication in patients receiving taxane-based anticancer drugs. Mortality rates are reported between 30 and 50%, mostly because of colon perforation and uncontrolled sepsis. Early diagnosis and immediate appropriate therapy affect the clinical outcome of NE (3, 4). We report a case of surgically treated NE in a patient who underwent docetaxel therapy for breast cancer.

Case Report
A 39-year-old woman with a diagnosis of breast carcinoma underwent breast conserving surgery for the right breast. Her past medical history explained that pathological examinations of the specimen revealed invasive ductal carcinoma, positive axillary lymph nodes, negative for estrogen and progesterone receptors and positive for C-erb B2. In this case of T1N1M0 breast cancer, she was treated with docetaxel (100 mg/m²), cyclophosphamide (650 mg/m²), and epirubicin (100 mg/m²) for the following months. Seven days after receiving the first dose of chemotherapy, she was presented to our emergency center with a 24 h history of diarrhea, vomiting, fever, and diffuse abdominal pain. On physical examination, her blood pressure was 90/50 mmHg, pulse rate was 100/min, and temperature was 38.9°C. Examination of the abdomen showed right lower quadrant tenderness with rebound and rigidity. A blood sample examination revealed severe neutropenia (0.164×10⁹/L) and leucopenia
and in some cases necrosis leading to perforation (7, 9). Pathologically, the disease is caused by bacterial invasion, increased bacterial proliferation due to decreased immunocompetence, production of bacterial endotoxin, intramural hemorrhage, ulceration, ischemia, and mucosal damage of the bowel, bacterial invasion, increased bacterial proliferation due to decreased immunocompetence, production of bacterial endotoxin, intramural hemorrhage, ulceration, ischemia, and in some cases necrosis leading to perforation (7, 9).

Bowel wall thickening demonstrated using CT or ultrasonography is one of the main proposed criteria to establish diagnosis and seems to be predictive of prognosis. Moreover, bowel wall thickening (>10 mm) is reported to be related to severe disease and a worse prognosis (3, 6, 8). Colonoscopy is not recommended because of a high risk of intestinal perforation (3, 8). Pathologically, the disease is caused by mucosal damage of the bowel, bacterial invasion, increased bacterial proliferation due to decreased immunocompetence, production of bacterial endotoxin, intramural hemorrhage, ulceration, ischemia, and in some cases necrosis leading to perforation (7, 9).

Although the management of NE is controversial, most authors recommend conservative therapy until maintaining normal neutrophil counts. Medical therapy includes bowel rest, intravenous fluids, parenteral nutrition, and broad-spectrum antibiotics. Patients should be closely monitored during the medical treatment and even following discharge because of the risk of relapse. Surgery is indicated in cases with peritonitis, persistent gastrointestinal bleeding, and clinical worsening despite aggressive medical therapy (3, 6, 8). Laparotomy should be delayed, if possible, until the absolute neutrophil count returns to normal (10).

Conclusion
Patients with breast carcinoma presenting with acute abdominal pain, neutropenia, and radiologically demonstrable bowel wall thickening under taxane-based chemotherapy should be suspected of NE because half of the patients are reported to have a fatal outcome in case of a diagnostic delay. Therefore, surgeons should gain more knowledge related NE to start prompt surgical therapy when appropriate.

Informed Consent: Written informed consent was obtained from patient who participated in this case.

Conflict of Interest: The authors declared no conflict of interest.

Financial Disclosure: The authors declared that this study has received no financial support.

References